Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Early endoscopy (1)
- Early endoscopy (2)
- Endoscopic therapy
- Adding a second therapy to epinephrine injection
- Mono or combined therapy?
- Mono or combined therapy? Risk of rebleeding
- Mono or combined therapy? Mortality
- Adding a sclerosant to epinephrine does not help
- Clips or Thermal?
- Clips or Thermal? Initial hemostasis
- Clips or Thermal? Rebleeding
- Choosing Clips or Thermal
- Clots: remove or leave it?
- EndoTx with iv PPI vs. iv PPI alone
- Clots: remove or leave it? Beneficial patients
- Clots: remove or leave it? Meta analysis (1)
- Clots: remove or leave it? Meta analysis (2)
- PPI before endoscopy?
- Pre emptive PPI (1)
- Pre emptive PPI (2)
- Adjuvant IV PPI?
- IV PPI cochrane review
- PUB Study: IV nexium vs. placebo
- Stigmata of haemorrhage
- Significantly less rebleeding
- Rebleeding within 30 days (ITT population)
- Mortality and surgery within 30 days
- Benefit irrespective of endoscopic Rx
- Benefit more Hp positive patients
- Second look endoscopy reduces rebleeding?
- Second look and selective retreatment
- Second look endoscopy
- Endoscopic retreatment vs. surgery (1)
- Endoscopic retreatment vs. surgery (2)
- Outcomes: endoscopic re-treatment and surgery
- What causes mortality?
- Proportion of non bleeding related deaths
- Non-bleeding related mortality (in-hospital death)
- Bleeding related mortality (in-hospital death)
- Should we stop aspirin?
- More recurrent bleeding with aspirin
- Yet, higher all-cause mortality without aspirin
- What have we learned? (1)
- What have we learned? (2)
Topics Covered
- Upper gastrointestinal bleeding is an important medical emergency
- The literature has provided many evidence-based management strategies
- Early endoscopy within 24 hours should be provided
- Injection for active ulcer bleeding should not be used as a monotherapy
- Thermal device (heat probe) is comparable to mechanical device (hemoclips)
- Underlying vessel beneath blood clot should exposed and treated
- Pre-endoscopy use of proton pump inhibitor may reduce need for endoscopic therapy
- Intravenous proton pump inhibitor is an important adjuvant to endoscopic therapy
- Routine second-look endoscopy is not recommended
- Surgery is still providing the ultimate hemostasis in selected cases
- Support of cardiopulmonary conditions is important to reduce mortality
- Anti-platelet agent should be restarted as soon as patient's condition stabilizes
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sung, J.J. (2011, January 5). Evidence-based management of non-variceal upper GI bleeding [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/HZVO4654.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Joseph J. Sung has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.